Physician profile
Robin Chalkley
NPI 1902246804
$2,949.17
in general payments reported to CMS, 2019-2025
27 companies · $1,510 in 2025
The $1,510 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2021: $239 · 2022: $374 · 2023: $68.03 · 2024: $641 · 2025: $1,510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,218.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $429.78 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $390.29 | 2021-2025 | |
| Aop Health US, LLC | $329.87 | 2025 | Rapiblyk |
| Pfizer INC. | $244.73 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $156.57 | 2024-2025 | Lifevest |
| Novo Nordisk INC | $149.01 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $140.20 | 2024-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $124.50 | 2019-2024 | Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $123.53 | 2022-2023 | Camzyos |
| Philips North America LLC | $113.17 | 2022-2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Merck Sharp & Dohme LLC | $111.11 | 2022-2025 | Verquvo |
| Lexicon Pharmaceuticals, INC. | $106.98 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $83.46 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.06 | 2021-2025 | Jardiance |
| Impulse Dynamics (USA) INC. | $60.11 | 2024 | Optimizer |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $52.51 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $40.19 | 2025 | Farxiga, Brilinta |
| Janssen Pharmaceuticals, INC | $39.51 | 2021-2022 | |
| Abiomed | $32.52 | 2025 | |
| Esperion Therapeutics, INC. | $29.66 | 2025 | Nexletol |
| Kestra Medical Technology Services, INC. | $24.35 | 2025 | Assure Wcd |
| Alnylam Pharmaceuticals INC. | $24.33 | 2025 | Onpattro |
| Regeneron Healthcare Solutions, INC. | $22.50 | 2025 | Evkeeza |
| Terumo Medical Corporation | $16.72 | 2019 | |
| Cvrx, INC. | $14.48 | 2025 | Barostim Neo System |
| Astellas Pharma US INC | $13.28 | 2021 | |
| Sanofi-Aventis U.S. LLC | $12.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Chalkley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.